Edition:
United Kingdom

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

26.97USD
7:41pm GMT
Change (% chg)

$3.31 (+13.99%)
Prev Close
$23.66
Open
$24.33
Day's High
$27.14
Day's Low
$23.30
Volume
178,825
Avg. Vol
170,528
52-wk High
$27.14
52-wk Low
$8.10

Latest Key Developments (Source: Significant Developments)

Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE.VOYAGER THERAPEUTICS INC - CONTINUE TO PLAN TO DOSE FIRST PATIENT IN PIVOTAL PHASE 2-3 PROGRAM FOR ADVANCED PARKINSON'S DISEASE DURING Q2.  Full Article

BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - BB Biotech Ag::BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING‍​.  Full Article

Voyager Therapeutics prices public offering of 4.50 mln common shares at $12/shr
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces pricing of public offering of common stock.Says public offering of 4.50 million common shares priced at $12.00per share.  Full Article

Voyager Therapeutics announces proposed offering of common stock
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces proposed offering of common stock.Voyager Therapeutics Inc - ‍commencing an underwritten public offering of $75 million of shares of its common stock​.  Full Article

Voyager Therapeutics reports Q3 GAAP loss per share $0.89
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics Inc reports third quarter 2017 financial results and corporate highlights.Q3 GAAP loss per share $0.89.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Voyager Therapeutics Inc - ‍total cash, cash equivalents, and marketable debt securities as of september 30, 2017 were $125.6 million​.Voyager Therapeutics Inc - ‍continues to expect to end 2017 with total cash, cash equivalents, and marketable debt securities of about $90 million to $100 million​.Voyager Therapeutics Inc - ‍existing cash, cash equivalents, marketable debt securities will be sufficient to fund operating expenses and capex requirements into 2019​.  Full Article

Voyager Therapeutics announces lead clinical candidate selection
Monday, 13 Feb 2017 

Voyager Therapeutics Inc : Voyager Therapeutics announces lead clinical candidate selection for monogenic form of amyotrophic lateral sclerosis (ALS) .Voyager Therapeutics-preclinical studies now underway to support filing of an investigational new drug application for VY-SOD101 during Q4 of 2017.  Full Article

Voyager Therapeutics Q2 gaap loss per share $0.37
Thursday, 11 Aug 2016 

Voyager Therapeutics Inc : Q2 gaap loss per share $0.37 . Voyager therapeutics provides second quarter 2016 investor update . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Voyager continues to expect to end 2016 with cash, cash equivalents and marketable securities of $160.0 million.  Full Article

Voyager Therapeutics reports Q1 loss per share of $0.29
Thursday, 12 May 2016 

Voyager Therapeutics Inc - : Voyager Therapeutics Inc says remain on track to deliver top-line, proof-of-concept clinical results for VY-AADC01 in Q4 . Remains on track to file an investigational new drug application in late 2017 for its pipeline program, VY-SOD101 for monogenic form of ALS . Voyager therapeutics provides first quarter 2016 investor update . Q1 loss per share $0.29 .Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration

* VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP POTENTIAL NEW TREATMENTS FOR ALZHEIMER’S DISEASE AND OTHER TAU-RELATED NEURODEGENERATIVE DISEASES